Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 15/20 | 0.68 |
| ▸ | LTB4R2 | Q9NPC1 | 6/20 | 0.68 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.68 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.68 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4809836 | 0.93 | AGTR1 (0.65) | AGTR1LTB4R2ABCB11GP6AGTR2 | |
| SCHEMBL4809851 | 0.93 | AGTR1 (0.65) | AGTR1LTB4R2ABCB11GP6AGTR2 | |
| SCHEMBL2930431 | 0.92 | AGTR1 (0.66) | AGTR1LTB4R2ABCB11GP6AGTR2 | |
| SCHEMBL2930427 | 0.92 | AGTR1 (0.66) | AGTR1LTB4R2ABCB11GP6AGTR2 | |
| SCHEMBL28456708 | 0.92 | AGTR1 (0.66) | AGTR1LTB4R2ABCB11GP6AGTR2 | |
| SCHEMBL8204220 | 0.89 | AGTR1 (0.71) | AGTR1LTB4R2ABCB11GP6AGTR2 | |
| SCHEMBL8818935 | 0.84 | AGTR1 (0.54) | AGTR1LTB4R2ABCB11GP6AGTR2 | |
| SCHEMBL8819112 | 0.84 | AGTR1 (0.54) | AGTR1LTB4R2ABCB11GP6AGTR2 | |
| SCHEMBL10109393 | 0.84 | AGTR1 (0.64) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL8263258 | 0.83 | AGTR1 (0.61) | AGTR1LTB4R2ABCB11GP6AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101782-B2 | Drug hybrid of rivastigmine or physostigmine with tranylcypromine, amoxapine, desipramine, nortriptyline, protriptyline, fluoxetine, fluvoxamine, paroxetine, duloxetine, betahistine, amlodipine, proylhexedrine, rimantadine, desloratadine; Alzheimer's disease; Parkinson's disease, impairment in memory | COLUCID PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101782-B2 | Drug hybrid of rivastigmine or physostigmine with tranylcypromine, amoxapine, desipramine, nortriptyline, protriptyline, fluoxetine, fluvoxamine, paroxetine, duloxetine, betahistine, amlodipine, proylhexedrine, rimantadine, desloratadine; Alzheimer's disease; Parkinson's disease, impairment in memory | COLUCID PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20080261950-A1 | Compounds that inhibit cholinesterase | COLUCID PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080261950-A1 | Compounds that inhibit cholinesterase | COLUCID PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261950-A1 | Compounds that inhibit cholinesterase | ACHE, BCHE, CHAT | AGTR1 2377/4885LTB4R2 1575/4885ABCB11 836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.